Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 96.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.14% |
| Mar 31, 2026 | -9.15% |
| Dec 31, 2025 | 142.40% |
| Sep 30, 2025 | 48.62% |
| Jun 30, 2025 | 51.66% |
| Mar 31, 2025 | 29.28% |
| Dec 31, 2024 | 45.64% |
| Sep 30, 2024 | 33.03% |
| Jun 30, 2024 | 62.24% |
| Mar 31, 2024 | 4.17% |
| Dec 31, 2023 | 40.59% |
| Sep 30, 2023 | 19.58% |
| Jun 30, 2023 | 15.37% |
| Mar 31, 2023 | -26.84% |
| Dec 31, 2022 | -31.67% |
| Sep 30, 2022 | -5.49% |
| Jun 30, 2022 | -4.25% |
| Mar 31, 2022 | -42.30% |
| Dec 31, 2021 | -10.61% |
| Sep 30, 2021 | 12.74% |